Clinical Trial Update: Bezlotoxumab Versus FMT for Multiple Recurrent CDI [Phase 4]

View source ↗

Summary

Phase 4 trial comparing bezlotoxumab to FMT for multiple recurrent Clostridioides difficile infection was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection
• Enterocolitis Pseudomembranous

Drugs mentioned

• Bezlotoxumab (bezlotoxumab)

Snippet

Sponsor: Leiden University Medical Center | Conditions: Clostridium Infections, Clostridioides Difficile | Phase 4 | Status: WITHDRAWN